Sustainability & Climate

A strategic acquisition, backed by Argonne Capital, sets the stage for major expansion in Texas's booming specialized lighting and holiday décor market.

With promising survival data and a pivotal Phase 3 trial underway, Imunon's localized immunotherapy could finally change the game for ovarian cancer.

Canada's largest charity polar bear dip returns, aiming to surpass $2.5 million raised for life-saving clean water projects in Ghana and Honduras.

Arizona State University just crossed $1 billion in research spending. This is the story of its disruptive rise and what it means for health, defense, and AI.

A new partnership aims to boost low colorectal cancer screening rates by combining trusted patient education with the promise of simpler blood-based tests.

A successful demonstration of Revoltz's compact electric cargo vehicle to Israeli officials could signal a major shift in last-mile logistics.

A father's life was saved by a quick-thinking guard and a connected AED. His story reveals a blueprint for how communities can fight sudden cardiac arrest.

Biotech pioneer Dr. Patrick Soon-Shiong is named a top influencer in oncology, boosting ImmunityBio amid strong sales and a promising drug pipeline.

HIZERO is launching a fleet of new cleaning gadgets at CES 2026, led by a handheld device that cleans, washes, and dries without noisy suction.

Tired of ads and algorithms? Gistvox has launched an audio-only app with a radical idea: intentional listening. But can its unique business model survive?

From building 75,000 homes to mastering commercial real estate, see how Shapell Properties has adapted and thrived through seven decades of change.

He helped land a Bible on the moon, but his final years were spent in state custody as his historic legacy became trapped in a bitter legal battle.

A seven-year investment in a Virginia apartment complex yields a 24% IRR, showcasing the power of patient capital and strategic renovations.

A landmark journal issue introduces a new framework for facial rejuvenation, moving beyond outdated norms to embrace individualized, culturally sensitive care.

After retiring $1.4M in toxic debt, QHSLab has secured fresh equity to scale its AI-driven primary care platform, marking a pivotal turnaround.

StimLabs secures FDA clearance for Theracor, the first-ever umbilical cord sheet device, offering new hope for patients with hard-to-heal chronic wounds.

Genmab discontinues its 'encouraging' lung cancer drug, acasunlimab, in a bold strategic pivot to accelerate its most promising late-stage assets.

A chiropractor with millions of followers claims he can reverse dementia. As science eyes a breakthrough, we examine the hope, the hype, and the business.

Setrusumab, a promising drug for Osteogenesis Imperfecta, failed to reduce fractures in key trials, triggering a market collapse and strategic overhaul.

Verisk terminates its $2.35B AccuLynx acquisition after FTC delays, triggering a $1.5B debt redemption and a potential legal battle with the spurned firm.